RYTM — Rhythm Pharmaceuticals, Inc.

Rhythm Pharmaceuticals Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Q1 2026 revenues totaled $60.1 million, reflecting a 5% sequential growth from Q4 2025.
• Geographic Breakdown: 61% of revenue was generated in the U.S., with the remaining 39% from international markets, which saw a 27% sequential increase in revenue.
• Operating Expenses: Total operating expenses were approximately $105.3 million, including $63.6 million in SG&A and $41.7 million in R&D, marking a significant increase from the previous year.
• Net Loss: GAAP EPS was a loss of $0.83 per share.
• Cash Position: The company ended the quarter with approximately $341 million in cash, expected to fund operations for at least the next 24 months.

2. Strategic Updates and Business Highlights

• Product Launch: The launch of IMCIVREE for acquired hypothalamic obesity (HO) is off to a strong start, with over 150 start forms received in the first six weeks post-approval.
• Market Expansion: The company is expanding its commercial organization, increasing sales reps from 16 to 42 to target the larger HO market, estimated at 10,000 patients in the U.S. and Europe.
• International Growth: The European Commission granted marketing authorization for IMCIVREE for HO, with launches anticipated in 2027. The company is also advancing towards approval in Japan, with a potential launch by the end of 2026.

3. Forward Guidance and Outlook

• Revenue Growth: The company expects steady growth in prescriptions for IMCIVREE throughout 2026, supported by ongoing education and engagement with healthcare providers.
• Operating Expenses: Guidance for non-GAAP operating expenses for 2026 remains unchanged at $385 million to $415 million.
• Clinical Trials: Anticipated milestones include sharing data from ongoing trials for Prader-Willi syndrome (PWS) and HO, with a focus on progressing towards a Phase III trial for bivamelagon by the end of 2026.

4. Bad News, Challenges, or Points of Concern

• Reimbursement Dynamics: While early approvals for reimbursement are positive, the company anticipates it will take 3 to 9 months for HO-specific IMCIVREE policies to be established among payers.
• Patient Transition Issues: The transition of patients to new insurance plans led to temporary increases in patients receiving free drug through the bridge program, which may affect revenue consistency.
• Launch Comparisons: There are concerns regarding whether the early success of the HO launch will be sustainable, as the company navigates the complexities of rare disease launches.

5. Notable Q&A Insights

• Patient Identification: The majority of start forms are from physicians previously engaged prior to approval, indicating effective pre-launch education efforts.
• Prescriber Dynamics: Most prescribers are new to IMCIVREE, with many having only prescribed to one patient so far, suggesting a need for ongoing education and engagement to drive further prescriptions.
• Market Potential: KOL feedback in Japan indicates strong belief in the efficacy of IMCIVREE, with a significant unmet need for treatment in that market.
• Clinical Data Expectations: Upcoming data presentations for PWS are anticipated to clarify the potential impact of setmelanotide on weight loss and satiety, which could influence future approvals and market perceptions.

Overall, Rhythm Pharmaceuticals is positioned for growth with the successful launch of IMCIVREE for acquired HO, although it faces challenges related to reimbursement and sustaining early momentum in patient adoption.